Clinical Trial: A Real-world Study on the Efficacy and Safety of Menin Inhibitors as Maintenance After Allo-HSCT

U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT07559695) titled 'A Real-world Study on the Efficacy and Safety of Menin Inhibitors as Maintenance After Allo-HSCT' on April 24.

Brief Summary: The objective of this observational study is to evaluate the efficacy and safety of menin inhibitor maintenance therapy in patients with acute leukemia who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Eligible patients will receive menin inhibitor maintenance therapy as part of their routine clinical practice. Acceptable agents include, but are not limited to, Revumenib, BN104, Ziftomenib, HMPL-506, or other menin-KMT2A interaction inhibitors. This study imposes no additional ...